Q4 2024 Earnings Call Transcript November 4, 2024 Hologic, Inc. reports earnings inline with expectations. Reported EPS is $1 ...

Hologic, Inc. HOLX reported adjusted earnings per share (EPS) of $1.01 in the fourth quarter of fiscal 2024, up 13.5% year ...

The firm reported a 13 percent jump in its non-COVID molecular diagnostics revenues year over year while its breast health and GYN Surgical business revenues rose 6 percent.

Good afternoon, and welcome to the Hologic's Fourth Quarter Fiscal 2024 Earnings Conference Call. My name is Shelly, and I am your operator for today’s call. Today's conference is being recorded. All ...

The agency is alerting patients and providers to not use the implantable devices, made for soft tissue such as breast tissue.

The last 12 months (to October 16, 2024) has seen the sale of a number of Cambridge’s life science and technology companies, ...

Hologic, Inc. focuses on women's health, projecting $4 billion in revenue for 2024. Learn why HOLX stock remains a compelling ...

Hologic has recalled the Biozorb devices after 188 reports of adverse events in patients who received the implants in breast ...

FDA and Hologic advise health providers to return all unused BioZorb Markers due to adverse events, including pain and ...

As Hologic gears up to cease operations at its Danbury, Connecticut facility in December, the Marlborough-based medical ...

The company committed to closing the facility, which makes breast health products, in late 2021 and gave most employees the ...

Hologic (Nasdaq: HOLX) notified the state of Connecticut that it plans to cut 86 jobs at its Danbury, Connecticut facility.